title: Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure.
abstract: Methamphetamine (MA) is an illegal stimulant drug of abuse with serious negative health consequences. The neurochemical effects of MA have been partially characterized, with a traditional focus on classical neurotransmitter systems. However, these directions have not yet led to novel drug treatments for MA abuse or toxicity. As an alternative approach, we describe here the first application of metabolomics to investigate the neurochemical consequences of MA exposure in the rodent brain. We examined single exposures at 3 mg/kg and repeated exposures at 3 mg/kg over 5 days in eight common inbred mouse strains. Brain tissue samples were assayed using high-throughput gas and liquid chromatography mass spectrometry, yielding quantitative data on >300 unique metabolites. Association testing and false discovery rate control yielded several metabolome-wide significant associations with acute MA exposure, including compounds such as lactate (p= 4.4 × 10-5,q= 0.013), tryptophan (p= 7.0 × 10-4,q= 0.035) and 2-hydroxyglutarate (p= 1.1 × 10-4,q= 0.022). Secondary analyses of MA-induced increase in locomotor activity showed associations with energy metabolites such as succinate (p= 3.8 × 10-7). Associations specific to repeated (5 day) MA exposure included phosphocholine (p= 4.0 × 10-4,q= 0.087) and ergothioneine (p= 3.0 × 10-4,q= 0.087). Our data appear to confirm and extend existing models of MA action in the brain, whereby an initial increase in energy metabolism, coupled with an increase in behavioral locomotion, gives way to disruption of mitochondria and phospholipid pathways and increased endogenous antioxidant response. Our study demonstrates the power of comprehensive MS-based metabolomics to identify drug-induced changes to brain metabolism and to develop neurochemical models of drug effects.
authors.affiliation: Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, McGuire Hall, 1112 East Clay Street, Richmond, VA 23298-0533, USA.
authors.forename: Joseph L
authors.initials: JL
authors.lastname: McClay
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Adkins
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Vunck
authors.forename: Angela M
authors.initials: AM
authors.lastname: Batman
authors.forename: Robert E
authors.initials: RE
authors.lastname: Vann
authors.forename: Shaunna L
authors.initials: SL
authors.lastname: Clark
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Beardsley
authors.forename: Edwin J C G
authors.initials: EJ
authors.lastname: van den Oord
keywords: Drugs of abuse; Inbred mice; Mass spectrometry; Neurotoxicity; Psychostimulants
references.citation: Am J Addict. 2004 Mar-Apr;13(2):181-90
references.pmid: 15204668
references.citation: NMR Biomed. 2009 May;22(4):419-25
references.pmid: 18985626
references.citation: Ann N Y Acad Sci. 2010 Feb;1187:101-21
references.pmid: 20201848
references.citation: Drug Alcohol Depend. 2002 Jun 1;67(1):73-9
references.pmid: 12062780
references.citation: Neuropsychopharmacology. 2009 Jan;34(1):173-86
references.pmid: 18843269
references.citation: J Neurosci Methods. 1994 Dec;55(2):173-82
references.pmid: 7723381
references.citation: J Cheminform. 2010 Oct 18;2(1):9
references.pmid: 20955607
references.citation: Neurosci Lett. 2002 Aug 2;328(1):55-9
references.pmid: 12123858
references.citation: Trends Biotechnol. 2004 May;22(5):245-52
references.pmid: 15109811
references.citation: J Neurochem. 2009 Apr;109(2):494-501
references.pmid: 19200336
references.citation: Psychopharmacology (Berl). 1976 Aug 17;48(3):271-5
references.pmid: 823582
references.citation: J Neurochem. 1985 Sep;45(3):935-9
references.pmid: 2411860
references.citation: Magn Reson Med. 1988 Feb;6(2):217-23
references.pmid: 3367778
references.citation: Arch Biochem Biophys. 1991 Jul;288(1):10-6
references.pmid: 1654816
references.citation: Annu Rev Pharmacol Toxicol. 2008;48:653-83
references.pmid: 18184107
references.citation: Biol Psychiatry. 2007 Jun 1;61(11):1272-80
references.pmid: 17097074
references.citation: Br J Clin Pharmacol. 2010 Jun;69(6):578-92
references.pmid: 20565449
references.citation: Brain Res. 2010 Jun 4;1335:1-13
references.pmid: 20385109
references.citation: Neuropsychopharmacology. 2010 Apr;35(5):1165-73
references.pmid: 20043005
references.citation: Neuroimage. 2011 Aug 1;57(3):866-72
references.pmid: 21624473
references.citation: Gen Dent. 2006 Mar-Apr;54(2):125-9; quiz 130
references.pmid: 16689071
references.citation: Neurotoxicol Teratol. 2006 Jul-Aug;28(4):509-16
references.pmid: 16814516
references.citation: Acad Emerg Med. 2008 Jan;15(1):23-31
references.pmid: 18211309
references.citation: Anal Chem. 2009 Aug 15;81(16):6656-67
references.pmid: 19624122
references.citation: Genome Res. 2004 Sep;14(9):1806-11
references.pmid: 15342563
references.citation: Science. 2011 Nov 11;334(6057):809-13
references.pmid: 22021672
references.citation: J Pharmacol Exp Ther. 1977 Apr;201(1):117-25
references.pmid: 191592
references.citation: Nature. 2006 Apr 20;440(7087):1073-7
references.pmid: 16625200
references.citation: Nat Protoc. 2011 Jun;6(6):743-60
references.pmid: 21637195
references.citation: Pharm Res. 2006 Jun;23(6):1075-88
references.pmid: 16715371
references.citation: Nucleic Acids Res. 2010 Jul;38(Web Server issue):W71-7
references.pmid: 20457745
references.citation: Prog Neurobiol. 2007 Feb;81(2):89-131
references.pmid: 17275978
references.citation: Brief Bioinform. 2007 Sep;8(5):279-93
references.pmid: 17626065
references.citation: Am J Psychiatry. 2005 Feb;162(2):361-9
references.pmid: 15677602
references.citation: Neurology. 2000 Mar 28;54(6):1344-9
references.pmid: 10746608
references.citation: Bioinformatics. 2009 Jul 15;25(14):1807-13
references.pmid: 19420056
references.citation: Arch Toxicol. 2012 Aug;86(8):1167-231
references.pmid: 22392347
references.citation: J Proteome Res. 2011 Feb 4;10(2):869-79
references.pmid: 21028881
references.citation: Psychopharmacology (Berl). 2009 Oct;206(3):479-89
references.pmid: 19649617
references.citation: Brain Res. 2012 Jan 6;1429:134-44
references.pmid: 22079322
references.citation: J Biol Chem. 2012 Feb 24;287(9):6336-49
references.pmid: 22228769
references.citation: Toxicology. 2011 Sep 5;287(1-3):29-37
references.pmid: 21645582
references.citation: Drug Alcohol Depend. 2011 Jan 15;113(2-3):133-8
references.pmid: 20739127
references.citation: Toxicol Pathol. 2009 Jun;37(4):521-35
references.pmid: 19458390
references.citation: Addiction. 2007 Apr;102 Suppl 1:44-8
references.pmid: 17493052
references.citation: J Proteome Res. 2011 Feb 4;10(2):705-13
references.pmid: 21028815
references.citation: Science. 2004 Jul 2;305(5680):99-103
references.pmid: 15232110
references.citation: Trends Genet. 2003 Oct;19(10):537-42
references.pmid: 14550627
references.citation: Anal Bioanal Chem. 2007 Jan;387(2):525-7
references.pmid: 16955259
references.citation: Chem Biol. 2010 Aug 27;17(8):831-40
references.pmid: 20797612
references.citation: Crit Rev Neurobiol. 2005;17(2):87-117
references.pmid: 16808729
references.citation: Neuropsychopharmacology. 2005 Dec;30(12):2125-34
references.pmid: 16123755
references.citation: Int Rev Neurobiol. 2009;88:43-64
references.pmid: 19897074
references.citation: Addiction. 2007 Aug;102(8):1204-11
references.pmid: 17565561
references.citation: Annu Rev Public Health. 2010;31:385-98
references.pmid: 20070191
references.citation: J Lipid Res. 2008 Jun;49(6):1187-94
references.pmid: 18204095
references.citation: J Inherit Metab Dis. 2009 Apr;32(2):135-42
references.pmid: 19020988
references.citation: Brain Res Rev. 2009 May;60(2):379-407
references.pmid: 19328213
references.citation: Psychol Rev. 1987 Oct;94(4):469-92
references.pmid: 3317472
references.citation: J Proteome Res. 2009 Apr;8(4):1943-52
references.pmid: 19714815
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5256-61
references.pmid: 15795384